Rapid Micro Biosystems, Inc. (RPID) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Rapid Micro Biosystems, Inc. is a life sciences technology company developing the Growth Direct platform for automated microbial quality control (MQC) testing in pharmaceutical manufacturing. The company is classified as an emerging growth company and a smaller reporting company. In July 2024, the company completed an enterprise-wide review leading to an "Operational Efficiency Program" involving workforce reductions and cost cuts.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $6.62 million | $5.00 million | $12.23 million | $10.04 million |
| Net Loss | $(12.58) million | $(14.02) million | $(25.90) million | $(27.90) million |
| Net Loss Per Share | $(0.29) | $(0.33) | $(0.60) | $(0.65) |
| Operating Cash Flow | — | — | $(25.64) million | $(25.88) million |
| Cash & Investments | $69.67 million (as of June 30, 2024) | |||
| Accumulated Deficit | $454.29 million (as of June 30, 2024) |
Gross Margin: The company reported a negative gross margin of approximately (3)% for Q2 2024, an improvement from (38)% in Q2 2023. For the six months ended June 30, 2024, the gross margin was (14)% compared to (37)% in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 32.3% year-over-year in Q2 2024, driven by a 43.2% increase in product revenue (higher system placements and LIMS software sales) and a 13.5% increase in service revenue.
- Cost Management: Total costs and operating expenses remained relatively flat year-over-year in Q2 2024 ($19.99 million vs. $20.06 million), despite revenue growth. General and administrative expenses decreased 13.5% due to lower headcount and the conclusion of a 2022 retention bonus program.
- System Placements: The company placed 5 systems in Q2 2024 compared to 2 in Q2 2023. Cumulative systems placed reached 149 as of June 30, 2024.
- Investment Portfolio: Short-term investments decreased from $67.77 million at year-end 2023 to $32.27 million at June 30, 2024, as maturities were used to fund operations.
Guidance, Outlook, and Risks
- Operational Efficiency Program: In July 2024, the company initiated cost-cutting measures including workforce reductions. Management expects these actions to generate approximately $7 million in annual cash savings and aims to achieve positive cash flow by the end of 2027 without additional financing. A charge of approximately $0.7 million is expected in Q3 2024 related to this program.
- Liquidity: Management believes existing cash, cash equivalents, and investments ($69.67 million) are sufficient to fund operations for at least 12 months following the report date.
- Nasdaq Listing Status: The company failed to regain compliance with the Nasdaq Global Select Market minimum bid price requirement ($1.00) by July 31, 2024. Consequently, the listing will transfer to the Nasdaq Capital Market on August 5, 2024, providing an additional 180-day compliance period. Failure to regain compliance by January 27, 2025, could result in delisting.
- Product Development: The company placed its first Rapid Sterility system in Q2 2024 and plans to scale manufacturing for this application in the second half of 2024.
- Risks: Key risks include the inability to achieve profitability, dependence on the commercial success of the Growth Direct platform, supply chain dependencies on single-source suppliers, and potential delisting from Nasdaq.
Investor Verification Checklist
- Path to Profitability: Verify the assumptions underlying the $7 million annual savings target and the timeline for achieving positive cash flow by end of 2027.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 bid price requirement during the 180-day compliance period on the Nasdaq Capital Market to avoid delisting.
- Recurring Revenue Mix: Track the percentage of recurring revenue (consumables and service contracts) relative to total revenue to assess the stability of the revenue base as system placements fluctuate.
- Inventory Levels: Review inventory balances ($21.43 million) against sales velocity to ensure no significant obsolescence risks, particularly given the negative gross margins.
- Customer Concentration: Note that Customer A represented 17.8% of revenue in Q2 2024; verify the stability of relationships with top customers.